GENE AND METABOLITE SIGNATURES IN CHRONIC MYELOID LEUKEMIA PROGRESSION: IMPLICATIONS FOR THERAPEUTIC RESISTANCE AND BIOMARKER DISCOVERY

Autor: Almeida, FC, Simões, RL, Berzoti-Coelho, MG, Ambrosio, L, Chaim, LFP, Figueiredo-Pontes, LL, Sorgi, CA, Faccioli, LH, Malta, TM, Castro, FA

Publikováno v: In Hematology, Transfusion and Cell Therapy October 2024 46 Supplement 4:S485-S486

The Human Developing Cerebral Cortex Is Characterized by an Elevated De Novo Expression of Long Noncoding RNAs in Excitatory Neurons.

Autor: Morales-Vicente DA; Laboratório de Ciclo Celular, Instituto Butantan, São Paulo, Brazil.; Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, Brazil., Tahira AC; Laboratório de Ciclo Celular, Instituto Butantan, São Paulo, Brazil., Woellner-Santos D; Laboratório de Ciclo Celular, Instituto Butantan, São Paulo, Brazil.; Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, Brazil., Amaral MS; Laboratório de Ciclo Celular, Instituto Butantan, São Paulo, Brazil., Berzoti-Coelho MG; Laboratório de Ciclo Celular, Instituto Butantan, São Paulo, Brazil.; Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, Brazil., Verjovski-Almeida S; Laboratório de Ciclo Celular, Instituto Butantan, São Paulo, Brazil.; Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, Brazil.

Publikováno v: Molecular biology and evolution [Mol Biol Evol] 2024 Jul 03; Vol. 41 (7).

Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms.

Autor: Cacemiro MDC; Laboratório de Fisiopatologia das Doenças Hematológicas, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo - USP, Av. do Café, s/nº. Campus Universitário, Ribeirão Preto, SP, 14040-903, Brazil. mairacacemiro@hotmail.com., Cominal JG; Laboratório de Fisiopatologia das Doenças Hematológicas, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo - USP, Av. do Café, s/nº. Campus Universitário, Ribeirão Preto, SP, 14040-903, Brazil., Pereira LM; Laboratório de Fisiopatologia das Doenças Hematológicas, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo - USP, Av. do Café, s/nº. Campus Universitário, Ribeirão Preto, SP, 14040-903, Brazil., Berzoti-Coelho MG; Laboratório de Fisiopatologia das Doenças Hematológicas, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo - USP, Av. do Café, s/nº. Campus Universitário, Ribeirão Preto, SP, 14040-903, Brazil., Berbel GM; Laboratório de Fisiopatologia das Doenças Hematológicas, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo - USP, Av. do Café, s/nº. Campus Universitário, Ribeirão Preto, SP, 14040-903, Brazil., Baroni L; Laboratório de Fisiopatologia das Doenças Hematológicas, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo - USP, Av. do Café, s/nº. Campus Universitário, Ribeirão Preto, SP, 14040-903, Brazil., Malta T; Laboratório de Fisiopatologia das Doenças Hematológicas, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo - USP, Av. do Café, s/nº. Campus Universitário, Ribeirão Preto, SP, 14040-903, Brazil., Tognon R; Department of Pharmacy, Federal University of Juiz de Fora, Campus Governador Valadares, Governador Valadares, MG, Brazil., Nunes NS; Laboratório de Fisiopatologia das Doenças Hematológicas, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo - USP, Av. do Café, s/nº. Campus Universitário, Ribeirão Preto, SP, 14040-903, Brazil., Souto EX; Euryclides de Jesus Zerbini Transplant Hospital, São Paulo, SP, Brazil., de Figueiredo-Pontes LL; Medical Imaging, Hematology and Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil., Yatsuda AP; Laboratório de Fisiopatologia das Doenças Hematológicas, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo - USP, Av. do Café, s/nº. Campus Universitário, Ribeirão Preto, SP, 14040-903, Brazil., de Castro FA; Laboratório de Fisiopatologia das Doenças Hematológicas, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo - USP, Av. do Café, s/nº. Campus Universitário, Ribeirão Preto, SP, 14040-903, Brazil. castrofa@fcfrp.usp.br.

Publikováno v: Medical oncology (Northwood, London, England) [Med Oncol] 2022 May 23; Vol. 39 (5), pp. 97. Date of Electronic Publication: 2022 May 23.

Bone Marrow Soluble Mediator Signatures of Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.

Autor: Cominal JG; Department of Clinical Analyses, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.; Center for Cell-Based Therapy, Regional Blood Center of Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., Cacemiro MDC; Department of Clinical Analyses, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.; Center for Cell-Based Therapy, Regional Blood Center of Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., Berzoti-Coelho MG; Department of Clinical Analyses, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.; Center for Cell-Based Therapy, Regional Blood Center of Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., Pereira IEG; Department of Clinical Analyses, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.; Center for Cell-Based Therapy, Regional Blood Center of Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., Frantz FG; Department of Clinical Analyses, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil., Souto EX; Department of Clinical Hematology, Euryclides de Jesus Zerbini Transplant Hospital, São Paulo, Brazil., Covas DT; Center for Cell-Based Therapy, Regional Blood Center of Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., de Figueiredo-Pontes LL; Center for Cell-Based Therapy, Regional Blood Center of Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.; Division of Hematology, Hemotherapy and Cellular Therapy, Department of Medical Imaging, Hematology, and Clinical Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., Oliveira MC; Center for Cell-Based Therapy, Regional Blood Center of Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.; Division of Rheumatology, Allergy and Immunotherapy, Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., Malmegrim KCR; Department of Clinical Analyses, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.; Center for Cell-Based Therapy, Regional Blood Center of Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil., de Castro FA; Department of Clinical Analyses, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.; Center for Cell-Based Therapy, Regional Blood Center of Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.

Publikováno v: Frontiers in oncology [Front Oncol] 2021 May 18; Vol. 11, pp. 665037. Date of Electronic Publication: 2021 May 18 (Print Publication: 2021).

Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis.

Autor: Hanniford D; Department of Pathology, New York University Langone Medical Center, New York, NY, USA; Interdisciplinary Melanoma Cooperative Group, New York University Langone Medical Center, New York, NY, USA. Electronic address: douglas.hanniford@nyulangone.org., Ulloa-Morales A; Department of Pathology, New York University Langone Medical Center, New York, NY, USA; Interdisciplinary Melanoma Cooperative Group, New York University Langone Medical Center, New York, NY, USA., Karz A; Department of Pathology, New York University Langone Medical Center, New York, NY, USA; Interdisciplinary Melanoma Cooperative Group, New York University Langone Medical Center, New York, NY, USA., Berzoti-Coelho MG; Department of Pathology, New York University Langone Medical Center, New York, NY, USA; Department of Clinical Analysis, Toxicology and Food Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, São Paulo, Brazil., Moubarak RS; Department of Pathology, New York University Langone Medical Center, New York, NY, USA; Interdisciplinary Melanoma Cooperative Group, New York University Langone Medical Center, New York, NY, USA., Sánchez-Sendra B; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain., Kloetgen A; Department of Pathology, New York University Langone Medical Center, New York, NY, USA; Interdisciplinary Melanoma Cooperative Group, New York University Langone Medical Center, New York, NY, USA., Davalos V; Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain., Imig J; Department of Pathology, New York University Langone Medical Center, New York, NY, USA; Interdisciplinary Melanoma Cooperative Group, New York University Langone Medical Center, New York, NY, USA., Wu P; Institute for Systems Genetics, New York University Langone Medical Center, New York, NY, USA., Vasudevaraja V; Applied Bioinformatics Laboratories, New York University Langone Medical Center, New York, NY, USA., Argibay D; Department of Pathology, New York University Langone Medical Center, New York, NY, USA; Interdisciplinary Melanoma Cooperative Group, New York University Langone Medical Center, New York, NY, USA., Lilja K; Department of Pathology, New York University Langone Medical Center, New York, NY, USA., Tabaglio T; Institute of Molecular and Cell Biology, A(∗)STAR, Singapore, Singapore., Monteagudo C; Department of Pathology, University of Valencia, Valencia, Spain., Guccione E; Institute of Molecular and Cell Biology, A(∗)STAR, Singapore, Singapore; Department of Oncological Sciences, Icahn School of Medicine, Mount Sinai, New York, NY, USA., Tsirigos A; Department of Pathology, New York University Langone Medical Center, New York, NY, USA; Applied Bioinformatics Laboratories, New York University Langone Medical Center, New York, NY, USA., Osman I; Departments of Urology and Medicine, New York University Langone Medical Center, New York, NY, USA; Interdisciplinary Melanoma Cooperative Group, New York University Langone Medical Center, New York, NY, USA., Aifantis I; Department of Pathology, New York University Langone Medical Center, New York, NY, USA; Interdisciplinary Melanoma Cooperative Group, New York University Langone Medical Center, New York, NY, USA., Hernando E; Department of Pathology, New York University Langone Medical Center, New York, NY, USA; Interdisciplinary Melanoma Cooperative Group, New York University Langone Medical Center, New York, NY, USA. Electronic address: eva.hernando-monge@nyulangone.org.

Publikováno v: Cancer cell [Cancer Cell] 2020 Jan 13; Vol. 37 (1), pp. 55-70.e15.